Causes and Treatment Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 82 Adult Patients |
Kim, Hye-In
(Department of Internal Medicine, Kyungpook National University School of Medicine)
Kim, Shin-Woo (Department of Internal Medicine, Kyungpook National University School of Medicine) Park, Ga-Young (Department of Internal Medicine, Kyungpook National University School of Medicine) Kwon, Eu-Gene (Department of Internal Medicine, Kyungpook National University School of Medicine) Kim, Hyo-Hoon (Department of Internal Medicine, Kyungpook National University School of Medicine) Jeong, Ju-Young (Department of Internal Medicine, Kyungpook National University School of Medicine) Chang, Hyun-Ha (Department of Internal Medicine, Kyungpook National University School of Medicine) Lee, Jong-Myung (Department of Internal Medicine, Kyungpook National University School of Medicine) Kim, Neung-Su (Department of Internal Medicine, Kyungpook National University School of Medicine) |
1 | Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008;7:598-605. DOI ScienceOn |
2 | Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-813. DOI ScienceOn |
3 | Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4:561-572. DOI ScienceOn |
4 | Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-1024. DOI ScienceOn |
5 | Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996;35(5 Pt 1):757-760. DOI |
6 | Mulvey JM, Padowitz A, Lindley-Jones M, Nickels R. Mycoplasma pneumonia associated with Stevens Johnson syndrome. Anaesth Intensive Care 2007;35:414-417. |
7 | Leigh IM, Mowbray JF, Levene GM, Sutherland S. Recurrent and continuous erythema multiforme: a clinical and immunological study. Clin Exp Dermatol 1985;10:58-67. DOI |
8 | Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153. DOI ScienceOn |
9 | Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40. DOI ScienceOn |
10 | Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669-1676. DOI |
11 | Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96. DOI ScienceOn |
12 | Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990- 1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-773. DOI ScienceOn |
13 | Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-129. DOI ScienceOn |
14 | Kim EJ, Lee JB, Kwon YH, et al. A clinical study of Stevens- Johnson syndrome and toxic epidermal necrolysis over the last five-year period in the Gwangju-Chonnam area. Korean J Dermatol 2006;44:574-578. |
15 | Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44. DOI ScienceOn |
16 | Jeung YJ, Lee JY, Oh MJ, Choi DC, Lee BJ. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010;2:123-126. DOI ScienceOn |
17 | Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010;85:131-138. DOI ScienceOn |
18 | Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165. DOI ScienceOn |
19 | Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology 1993;186:32-37. DOI ScienceOn |
20 | Stewart MG, Duncan NO 3rd, Franklin DJ, Friedman EM, Sulek M. Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 1994;111(3 Pt 1):236-242. |
21 | Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-278. DOI ScienceOn |
22 | Pushker N, Tandon R, Vajpayee RB. Stevens-Johnson syndrome in India-risk factors, ocular manifestations and management. Ophthalmologica 2000;214:285-288. DOI ScienceOn |
23 | French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16. DOI ScienceOn |
24 | Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200. DOI ScienceOn |
25 | Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144-148. DOI ScienceOn |
26 | Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 2009;147:1004-1011. DOI ScienceOn |
27 | Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005;65:2085-2090. DOI ScienceOn |
28 | Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-88. DOI ScienceOn |
29 | Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-255. DOI ScienceOn |
![]() |